Acne is an inflammatory condition affecting the hair follicles and sebaceous glands of the skin. It affects nearly 85% of adolescents and persists into adulthood for some people. The bacterium Cutibacterium acnes plays a key role in the development of the condition. When the skin’s pores become clogged with dead skin cells and oil, the bacteria have an opportunity to multiply, causing inflammation and redness.
Against this backdrop, Sanofi is developing an experimental vaccine based on mRNA technology. It is designed to stimulate the body’s immune system against a specific protein of the bacterium known as CAMP2.
Two Phase 1 and Phase 2 clinical trials are currently being conducted with 1,028 participants aged 18 to 45. The trials are assessing the vaccine’s safety, the body’s immune response and the extent to which acne improves.
Despite this scientific progress, experts point out that the vaccine remains in the research and testing stages, and its ultimate effectiveness in humans has not yet been fully established.







